|Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia|
SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ...
New England Journal of Medicine 348 (11), 994-1004, 2003
|Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia|
BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ...
New England Journal of Medicine 355 (23), 2408-2417, 2006
|European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013|
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...
Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013
|Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia|
G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ...
New England Journal of Medicine 362 (24), 2251-2259, 2010
|Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet|
M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ...
Blood 108 (6), 1809-1820, 2006
|Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet|
M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ...
Journal of clinical oncology 27 (35), 6041, 2009
|Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia|
TP Hughes, J Kaeda, S Branford, Z Rudzki, A Hochhaus, ML Hensley, ...
New England Journal of Medicine 349 (15), 1423-1432, 2003
|Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL …|
T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ...
Blood 108 (1), 28-37, 2006
|BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros|
CG Mullighan, CB Miller, I Radtke, LA Phillips, J Dalton, J Ma, D White, ...
Nature 453 (7191), 110-114, 2008
|Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia|
KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ...
New England journal of medicine 371 (11), 1005-1015, 2014
|Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia|
A Hochhaus, SG O'brien, F Guilhot, BJ Druker, S Branford, L Foroni, ...
Leukemia 23 (6), 1054-1061, 2009
|A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias|
JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ...
New England Journal of Medicine 369 (19), 1783-1796, 2013
|Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding …|
S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, ...
Blood 102 (1), 276-283, 2003
|Dynamics of chronic myeloid leukaemia|
F Michor, TP Hughes, Y Iwasa, S Branford, NP Shah, CL Sawyers, ...
Nature 435 (7046), 1267-1270, 2005
|High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute …|
S Branford, Z Rudzki, S Walsh, A Grigg, C Arthur, K Taylor, R Herrmann, ...
Blood, The Journal of the American Society of Hematology 99 (9), 3472-3475, 2002
|International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed …|
M Deininger, SG O'Brien, F Guilhot, JM Goldman, A Hochhaus, ...
Blood 114 (22), 1126, 2009
|Lin28 promotes transformation and is associated with advanced human malignancies|
SR Viswanathan, JT Powers, W Einhorn, Y Hoshida, TL Ng, S Toffanin, ...
Nature genetics 41 (7), 843-848, 2009
|Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy|
A Hochhaus, HM Kantarjian, M Baccarani, JH Lipton, JF Apperley, ...
Blood 109 (6), 2303-2309, 2007
|Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study|
DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ...
Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013
|Long-term outcomes of imatinib treatment for chronic myeloid leukemia|
A Hochhaus, RA Larson, F Guilhot, JP Radich, S Branford, TP Hughes, ...
New England Journal of Medicine 376 (10), 917-927, 2017